Gang Wang
Direktor/Vorstandsmitglied bei SHANGHAI JUNSHI BIOSCIENCES CO., LTD.
Aktive Positionen von Gang Wang
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| SHANGHAI JUNSHI BIOSCIENCES CO., LTD. | Direktor/Vorstandsmitglied | 20.10.2023 | - |
| Corporate Officer/Principal | 29.08.2019 | 20.10.2023 | |
| OBIO TECHNOLOGY (SHANGHAI) CORP., LTD. | Direktor/Vorstandsmitglied | 29.12.2020 | - |
| Independent Dir/Board Member | 29.12.2020 | - | |
Hrain Biotechnology Co., Ltd.
 Hrain Biotechnology Co., Ltd. BiotechnologyHealth Technology Hrain Biotechnology Co., Ltd. engages in the research and development, and production of immune cell therapy products. It offers chimeric antigen receptor (CAR) T-cell therapy, chimeric antigen receptor-transduced natural killer (CAR-NK) cell therapy, dash chimeric antigen receptor (CAR) T-cell therapy. The company was founded by Pin Wang on July 20, 2015 and is headquartered in Shanghai, China. | Direktor/Vorstandsmitglied | 18.06.2021 | - |
| Independent Dir/Board Member | 18.06.2021 | - |
Karriereverlauf von Gang Wang
Ausbildung von Gang Wang
| Dartmouth Medical School | Doctorate Degree |
Statistik
International
| China | 4 |
| Vereinigte Staaten | 2 |
Operativ
| Director/Board Member | 3 |
| Independent Dir/Board Member | 2 |
| Corporate Officer/Principal | 1 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| SHANGHAI JUNSHI BIOSCIENCES CO., LTD. | Health Technology |
| OBIO TECHNOLOGY (SHANGHAI) CORP., LTD. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Hrain Biotechnology Co., Ltd.
Hrain Biotechnology Co., Ltd. BiotechnologyHealth Technology Hrain Biotechnology Co., Ltd. engages in the research and development, and production of immune cell therapy products. It offers chimeric antigen receptor (CAR) T-cell therapy, chimeric antigen receptor-transduced natural killer (CAR-NK) cell therapy, dash chimeric antigen receptor (CAR) T-cell therapy. The company was founded by Pin Wang on July 20, 2015 and is headquartered in Shanghai, China. | Health Technology |
